Cited by 533Neonatal Respiratory Health ResearchAngiogenesis and VEGF in CancerRespiratory Support and Mechanisms

Vascular Endothelial Growth Factor Gene Therapy Increases Survival, Promotes Lung Angiogenesis, and Prevents Alveolar Damage in Hyperoxia-Induced Lung Injury: Evidence That Angiogenesis Participates in Alveolarization

Thébaud, Bernard, Ladha, Faruqa, Michelakis, Evangelos D., Sawicka, Monika, Thurston, Gavin, Eaton, Farah, Hashimoto, Kyoko, Harry, Gwyneth +3 more·2005·Circulation

Abstract

Background— Bronchopulmonary dysplasia (BPD) and pulmonary emphysema, both significant global health problems, are characterized by a loss of alveoli. Vascular endothelial growth factor ( VEGF) is a trophic factor required for endothelial cell survival and is abundantly expressed in the lung. Methods and Results— We report that VEGF blockade decreases lung VEGF and VEGF receptor 2 (VEGFR-2) expression in newborn rats and impairs alveolar development, leading to alveolar simplification and loss of lung capillaries, mimicking BPD. In hyperoxia-induced BPD in newborn rats, air space enlargement and loss of lung capillaries are associated with decreased lung VEGF and VEGFR-2 expression. Postnatal intratracheal adenovirus-mediated VEGF gene therapy improves survival, promotes lung capillary formation, and preserves alveolar development in this model of irreversible lung injury. Combined VEGF and angiopoietin-1 gene transfer matures the new vasculature, reducing the vascular leakage seen in VEGF-induced capillaries. Conclusions— These findings underscore the importance of the vasculature in what is traditionally thought of as an airway disease and open new therapeutic avenues for lung diseases characterized by irreversible loss of alveoli through the modulation of angiogenic growth factors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.105.541524

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Such VEGF upregulation may have important clinical implications since VEGF and Ang-1 have been shown to play pivotal roles in angiogenesis, alveolar development, and treatment of acute lung injury (ALI).

    “Such upregulation may have important clinical implications since VEGF and Ang-1 have been shown to play pivotal roles in angiogenesis, alveolar development, and treatment of acute lung injury (ALI) [8, 57–60].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Healy AM, Morgenthau L, Zhu X, Farber HW, Cardoso WV. VEGF is deposited in the subepithelial matrix at the leading edge of branching airways and stimulates neovascularization in the murine embryonic lung. Dev Dyn. 2000;219:341-352.
  2. Ng YS, Rohan R, Sunday ME, Demello DE, D'Amore PA. Differ- ential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn. 2001;220:112-121.
  3. Gebb SA, Shannon JM. Tissue interactions mediate early events in pulmonary vasculogenesis. Dev Dyn. 2000;217:159 -169.

Cited by

Sorted by citations

Authors
Thébaud, B., Ladha, F., Michelakis, E. D., Sawicka, M., Thurston, G., Eaton, F., Hashimoto, K., Harry, G., Haromy, A., Korbutt, G., & Archer, S. L.
Affiliations
  • From the Vascular Biology Research Group (B.T., F.L., E.D.M., M.S., F.E., K.H., G.H., A.H., S.L.A.), the Department of Pediatrics, Division of Neonatology (B.T.), the Department of Medicine (E.D.M., S.L.A.), the Surgical-Medical Research Institute (G.K.), and the Department of Physiology (S.L.A.), University of Alberta, Edmonton, Canada; and Regeneron Pharmaceuticals Inc, Tarrytown, NY (G.T.).
  • University of Alberta (CA)
Venue
Circulation
Published
2005-10-18
Volume
112
Issue
16
Pages
2477-2486
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2120215146
Cited by
533
References
53
Citations by year
2026: 10 · 2025: 18 · 2024: 16 · 2023: 16 · 2022: 14 · 2021: 44 · 2020: 36 · 2019: 25 · 2018: 26 · 2017: 23 · 2016: 36 · 2015: 31 · 2014: 37 · 2013: 38 · 2012: 30
FWCI
15.71
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Heart and Stroke Foundation of Canada
  • Stollery Children’s Hospital Foundation
  • Children's Hospital Foundation
  • Fondation pour la Recherche Médicale
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (R01HL071115)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Neonatal Respiratory Health Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
Keywords
vascular endothelial growth factor, VEGF gene therapy, VEGFR2, bronchopulmonary dysplasia, hyperoxia-induced lung injury, alveolar development, alveolar damage, angiopoietin-1, adenoviral gene transfer, vascular leakage, neonatal rats
MeSH terms
Adenoviridae, Angiography, Animals, Animals, Newborn, Bronchopulmonary Dysplasia, Disease Models, Animal, Endothelium, Vascular, Genetic Vectors, Humans, Infant, Newborn, Lung, Pulmonary Alveoli, Pulmonary Artery, Genetic Therapy, Hyperoxia, Neovascularization, Physiologic, Vascular Endothelial Growth Factor A, Rats, Lung Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review